Best of IDWeek 2022

Article

Experts discuss a range of the most topical infectious disease research, presented at the recent IDWeek 2022 conference.

For the first time in 3 years, the IDWeek conference was held in-person.

Contagion was there, covering the latest developments in infectious disease research. Here's a roundup of some of our favorite interviews, featuring a range of the most significant topics covered at this year's conference.

What makes Novavax’s COVID-19 booster different? The adjuvanted vaccine “has kept recognizing variants that arise,” says Novavax executive director Germán Áñez, MD.


Adjuvanted Novavax Booster Adapts to New Variants

What makes Novavax’s COVID-19 booster different? The adjuvanted vaccine “has kept recognizing variants that arise,” says Novavax executive director Germán Áñez, MD.

After Helen Boucher, MD, gave the Maxwell Finland presentation she spoke of the continuing issues as well as the encouraging aspects that have institutions working on the problem.

AMR: Perils and Progress

After Helen Boucher, MD, gave the Maxwell Finland presentation she spoke of the continuing issues as well as the encouraging aspects that have institutions working on the problem.

A late-breaking IDWeek 2022 study found high seroprotection was achieved among people living with HIV after receiving 3 doses of a hepatitis B vaccine.

“It’s Potentially Game-Changing”: Hepatitis B Vaccination Protects People Living With HIV

A late-breaking IDWeek 2022 study found high seroprotection was achieved among people living with HIV after receiving 3 doses of a hepatitis B vaccine.

A member of the Infectious Diseases Society of America (IDSA) leadership feels there is some inroads being made in Congress for this antimicrobial resistance legislation.

Building Momentum for the Pasteur Act

Amanda Jezek, senior vice president of public policy and government relations at IDSA, feels Congress is making significant progress toward antimicrobial resistance legislation.

During a late breaking session at ID Week, an investigator presented data on the GSK vaccine that is in development.

Investigational RSV Vaccine for Seniors Demonstrates Efficacy and Safety

During a late breaking session at ID Week, an investigator presented data on the GSK vaccine that is in development.

Recent Videos
© 2024 MJH Life Sciences

All rights reserved.